Scholarly article on topic 'Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway'

Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway Academic research paper on "Basic medicine"

0
0
Share paper
Academic journal
J Biomed Sci
OECD Field of science
Keywords
{""}

Academic research paper on topic "Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway"

NSC

The cost of publication in Journal of Biomedical Science Is borne by the National Science Council,Taiwan

RESEARCH Open Access

Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway

14- 14- 1 11 1 7 1 1*

Jia Y Guo ', Tong Yang ', Xiang G Sun , Ni Y Zhou , Fu S Li , Dan Long , Tao Lin , Ping Y Li and Li Feng

JOURNAL OF BIOMEDICAL SCIENCE

Abstract

Background: Ischemic postconditioning (IPO) has been demonstrated to attenuate ischemia/reperfusion (I/R) injury in the heart and brain, its roles to liver remain to be defined. The study was undertaken to determine if IPO would attenuate liver warm I/R injury and its protective mechanism.

Methods: Mice were divided into sham, I/R, IPO+I/R (occlusing the porta hepatis for 60 min, then treated for three cycles of 1 0 sec brief reperfusion consecutively, followed by a persistent reperfusion); L-NAME+ sham (L-NAME, 1 6 mg/kg, i.v., 5 min before repefusion); L-NAME+I/R; and L-NAME+ IPO. Blood flow of caudate and left lobe of the liver was blocked. Functional and morphologic changes of livers were evaluated. Contents of nitric oxide, eNOS and iNOS in serum were assayed. Concentration of eNOS, iNOS, malondialdehyde (MDA) and activity of superoxide dismutase (SOD) in hepatic tissue were also measured. Expressions of Akt, p-Akt and HIF-1a protein were determined by western blot. Expressions of TNF-a and ICAM-1 were measured by immunohistochemistry and RT-PCR.

Results: IPO attenuated the dramatically functional and morphological injuries. The levels of ALT was significantly reduced in IPO+I/R group (p < 0.05). Contents of nitric oxide and eNOS in serum were increased in the IPO+I/R group (p < 0.05). IPO also up-regulated the concentration of eNOS, activity of SOD in hepatic tissue (p < 0.05), while reduced the concentration of MDA (p < 0.05). Moreover, protein expressions of HIF-1a and p-Akt were markedly enhanced in IPO+I/R group. Protein and mRNA expression of TNF-a and ICAM-1 were markedly suppressed by IPO (p < 0.05). These protective effects of IPO could be abolished by L-NAME.

Conclusions: We found that IPO increased the content of NO and attenuated the overproduction of ROS and I/R-induced inflammation. Increased NO contents may contribute to increasing HIF-1a level, and HIF-1a and NO would simultaneously protect liver from I/R injury. These findings suggested IPO may have the therapeutic potential through Akt-eNOS-NO-HIF pathway for the better management of liver I/R injury.

Background

Multiple studies have shown that ischemic preconditioning (IPC), defined as one or more brief ischemic insult, confers organ protection from I/R injury [1,2]. Although IPC has shown protective effects against I/R injury, its utilization as clinical strategy is largely limited because the onset of ischemia is difficult to be predicted.

* Correspondence: feng31@sohu.com t Contributed equally

1Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P. R. China

Fulllist of author information is available at the end of the article

Bio Med Central

However, the onset of reperfusion is more predictable. Recently, a new strategy, named ischemic postcondition-ing (IPO), was described by Zhao et al [3] and showed promising results for cardiac reperfusion injury. It consists in application of several brief cycles of ischaemia and reperfusion, made soon after the ischemia phase and before reperfusion phase [3,4]. This method was used successfully in heart [5,6], brain [7], kidney [8,9], spinal cord [10], intestine [11] and, recently, a few study that demonstrate its efficacy in liver [12-14] I/R injury. Although the protective effects of IPO on several organs have been identified, the interventions among the multiple and interacting components involved in IPO remains

© 2011 Guo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

unclearly understood. And so far, the exact protective mechanism of IPO on liver I/R injury have not been completely elucidated.

Several studies have suggested that NO protects organs against I/R injury [15,16]. The potentially protective role of endogenous NO in liver I/R injury is also supported by several studies. There is evidence implicating NO is involved in the heart [17] and kidney [18] protections of ischemic postconditioning, but there was no information as to whether NO participates in the protective response elicited by liver IPO.

Studies have shown that NO can upregulate the rate of hypoxia inducible factor-1a (HIF-1a) synthesis by activating the phosphatidylinositol 3-kinase (PI3K)-Akt [19,20] and blocks proline hydroxylase (PHD) activity [19]. Activation and upregulation of HIF-1a has been recently found to be able to protect liver from I/R [21,22]. Several studies also indicated that the PI3K/Akt pathway plays an important role in protective action of IPO [23,24], but mechanism by which PI3K/Akt pathway is involved in the liver IPO remain poorly understood. Furthermore, Akt is important in the activation of eNOS mediated NO production [25]. Studies have shown that cardioprotection is associated with NO production following Akt-mediated eNOS activation [26,27]. So we wonder if IPO treatment may have protective role against liver I/R injury through Akt-NO-HIF pathway. As such, the present study was undertaken to investigate the more detailed protective mechanism of IPO on liver I/R injury. Our data indicate that IPO may have the therapeutic potential through Akt-eNOS-NO-HIF pathway for the better management of liver I/R injury.

Materials and methods

N-nitro-L-arginine methylester (L-NAME)

N-nitro-L-arginine methylester (L-NAME), a non-selective nitric oxide synthase (NOS) inhibitor, were purchased from Sigma (St. Louis, MO, USA). In this study, L-NAME was dissolved and diluted with saline.

Animal model of 70% liver I/R injury

Male BALB/c mice (weight, 20-25 g) were used as experimental animals, maintained on a standard diet and water ad libitum, and kept in a temperature-controlled environment (20°C to 22°C) with alternating 12hour cycles of light and dark. Six groups were studied (n = 16/group): Group I, sham group; group II, I/R group; group III, IPO+I/R group (occlusing the porta hepatis for 60 min, then treated for three cycles of 10 sec brief reperfusion consecutively, followed by a persistent reperfusion); group IV, L-NAME+sham (L-NAME, 16 mg/kg, i.v., 5 min before reperfusion); group V, L-NAME+I/R; and group VI, L-NAME+ IPO. After a

midline laparatomy incision, an atraumatic vascular clip was placed on the vessels blocking the portal venous and hepatic arterial blood supply to the median and left lateral lobes of the liver, which results in approximately 70% mouse liver I/R injury. The animals were placed on a heating table to maintain core body temperature at 37°C. After 55 min ischemia, 5 min before reperfusion, L-NAME was injected through the tail vein. Sham-operated animals went through the same surgical procedure as other animals; however, hepatic vessels clip were not applied. Animals were killed at 2, 4 and 12 hours after liver I/R injury or sham surgery. Liver tissues and blood samples were taken for analysis. This study was approved by Sichuan Bioethics Committee, and all protocols were conducted under the guidelines of Animal Care and Use.

Serum alanine aminotransferase (ALT), NO, and NOS

Blood samples were obtained at the time of sacrifice. The serum concentration of alanine aminotransferase (ALT) was measured in a clinical laboratory as markers of hepatic functional damage. The serum levels of NO and NOS were determined by using an NO and NOS Kit (Jiancheng Biotech Ltd, Nanjing, China) according to the manufacture' instructions.

Histopathologic analysis

Tissue samples taken at the time of sacrifice after hepatic I/R injury were fixed in 10% buffered formalin solution and embedded in paraffin. Sections at 5 ^m intervals were prepared and processed for H&E staining. Histological changes were scored in a blind fashion from 0 to 3 based on the degree of cytoplasmic vacuoli-zation, sinusoidal congestion, sinusoidal derangement, and necrosis of parenchymal cells using modified Suzuki classification as described by Takeda et al [28].

Determination of malondialdehye (MDA) level, total superoxide dismutase (SOD) activity, and nitricoxide synthase (NOS) in tissue

The involvement of ROS in I/R includes increased lipid peroxidation (LPO). LPO causes production of secondary products, among which MDA is used widely as a marker of oxidative stress. Levels of MDA in 2 hours post-ischemic livers were measured as previously described [29]. Liver samples were homogenized and trichloroacetic acid was added to the homogenate, followed by addition of TBA-water solution to the supernatant and boiling for 60 minutes. After samples were cooled down, the optical density of supernatant at 532 nm was measured. Total SOD activity was determined by monitoring the concentration of nitroblue tet-razolium, which was reduced to a water-insoluble blue formazan dye with an absorbance maximum at about

560 nm by superoxide anion generated by xanthine-xanthine oxidase as previously described [30]. Data are expressed as mean ± SD. NOS contents were assayed by using NOS assay kit (Jiancheng Biotech Ltd, Nanjing, China) according to the manufactures' instructions.

Measurement of hepatic TNF-a and ICAM-1 mRNA levels

Total RNA was extracted from liver tissues using TRIzol reagent (Invitrogen, Carlsbad, CA). For semiquantitative PCR analysis, cDNA samples were standardized based on the content of b-actin cDNA as a housekeeping gene. RNA (1 ^g) was reverse-transcribed and amplified using TaKaRa One-Step RT-PCR Kit (Takara Shuzo Co., Japan) at following RT-PCR conditions: 95°C for 2 min, 30 cycles at 95°C for 1 min, 59°C for 90 seconds, and 72°C for 2 min. Primers used in PCR reactions were as follows: TNF-a 5' primer (5'-AGCCCACGTAGCAAACCACCAA-3') and 3' primer (5'-ACACCCATTCCCTTCACAGAG-CAAT-3'); ICAM-1 5' primer (5'-TGGAACTGCACGTG CTGTAT-3') and 3' primer (5'-ACCATTCTGTTCA AAAGCAG-3');

and b-actin 5' primer (5'-CTGAAGTACCCCATTGAA-CATGGC-3') and 3' primer (5'-CAGAGCAG-TAATCTCCTTCTGCAT-3'). PCR products were stained with ethidium bromide and electrophoresed in a 1.5% agarose gel. The target bands were visualized with an ultraviolet illuminator (Gel Doc EQ) (Bio-Rad Laboratories Inc., Hercules, CA) and image analysis software (QUANTITY ONE) (Bio-Rad). The mRNA expressions of TNF-a and ICAM-1 were presented as percent of b-actin.

Protein expression of HIF-1a, p-Akt and Akt

Proteins were extracted from hepatic tissues and quantified using the Bradford assay (Bio-Rad). Equal amounts of protein (40 ^g) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad). After overnight blocking at 4°C, the membranes were incubated and shaken for 2 h at 37 °C with a mouse monoclonal antibody against HIF-1a (diluted 1:500, AbCam, Canbridge, UK); p-Akt (diluted 1:500, Signalway Antibody); rabbit polyclonal antibody against Akt (diluted 1:500, Signal-way Antibody); followed by a secondary antibodies (diluted 1:2000, Santa Cruz, CA). The signals were detected by using an ECL kit(Millipore, Bedford, MA, USA). The membranes were re-incubated with a mouse monoclonal antibody against glyceraldehydes 3-phos-phate dehydrogenase (GAPDH) (diluted 1:10,000, Santa Cruz, CA) to control for protein loading.

Immunohistochemistry for TNF-a and ICAM-1

Tissue samples taken at the time of sacrifice after liver I/R injury were fixed in 10% buffered formalin and

embedded in paraffin. Sections at 5 ^m intervals were stained with primary rabbit anti-mouse mAbs against TNF-a (diluted, 1:500, Santa Cruz, CA) or ICAM-1 (diluted, 1:500, Santa Cruz, CA). After incubation, the sections were incubated with a biotinylated rabbit anti-mouse IgG. Then the samples were incubated with per-oxidase-labeled streptavidin. DAB solution was added to the samples, and the colorimetric reaction was allowed to proceed for 1 min. The estimates were performed by a blinded pathologist (3 to 4 sections per liver and 10 to 12 fields per section).

Statistical analysis

All data were expressed as mean ± SD. Data were analyzed using ANOVA for multiple comparisons. Analysis between two groups was performed using unpaired Student's t test (two-tailed) where ANOVA indicated significance for the multiple comparison. P values of less than 0.05 were considered as significant differences.

Results

Physiological function of IPO in hepatic I/R injury

To determine if IPO was able to attenuate I/R injury, 3 cycles of 10s of reperfusion followed by 10s ischemia immediately after 60 min ischemia of the medium and left liver lobes were applied to the IPO+I/R group. Serum levels of ALT were measured after 2 h of reperfusion following 60 min of ischemia and were significantly different among the groups. Compared with sham-operated control mice, I/R mice showed significant increases in ALT. IPO treatment significantly reduced all serum levels of ALT compared to I/R group (Figure 1). Subsequent determination of transaminases levels at 4, 12 h of reperfusion showed maintained low values in mice post-treated with IPO but high levels in I/R group (data not shown).

Protective effect of IPO on the liver tissue from I/R injury

To further confirm the protective effect of IPO on hepatic I/R injury, sections of the liver obtained from the ischemic lobe at 2 h after reperfusion were evaluated for histopathological analysis. Compared with sham-operated control group(Figure 2A), I/R mice liver tissue showed significant cytoplasmic vacuolization, sinusoidal congestion, extensive hepatic cellular necrosis and massive cellular infiltration (Figure 2B). However, the parenchymal appearance was near normal in IPO+I/R group. Mild cellular infiltration, few necrosis as well as comparatively preserved lobular architecture were seen in the liver treated with IPO (Figure 2C). In the evaluation of the histological features of I/R injury, the IPO+I/ R group had significantly lower scores of cytoplasmic vacuolization and massive necrosis compared with the I/ R group (Figure 2D). L-NAME abolished the protective

slmn sham—L I.R IR+L IPO-I R IPO-L

Figure 1 ALT levels after reperfusion. After 60 minutes of ischemia and 2 hours of reperfusion, serum levels of ALT were determined. Compared with sham-operated controlmice, I/R mice showed significant increases in ALT. The post-treatment of IPO significantly reduced all serum levels of ALT compared to I/R group. "+L" means "+L-NAME". For allgroups, n = 8. * p < 0.05 compared to sham group. ' p < 0.05 compared to IPO+I/R group.

effect of IPO post-treatment with increased cytoplasmic vacuolization and hepatocellular necrosis (Figure 2D).

IPO reduces oxidative stress in liver tissues

To assess the effect of IPO on oxidative stress after liver I/R, MDA and activity of superoxide dismutase (SOD)

were measured. Hepatic 60 min ischemia and 2 hours of reperfusion caused substantial increase in liver MDA levels and marked decrease in liver SOD activity compared with IPO+I/R group (Figure 3). In the post-treatment of IPO, the liver MDA content reduced 64.11% and liver SOD activity was elevated by 27.68%.

sinusoidal congestion vacuolization

Figure 2 Hepatic histological changes in mice subjected to I/R. (A): sham, (B): I/R, (C): IPO+I/R. Hematoxylin-eosin-stained liver sections from animals undergoing 60 minutes ischemia and 2 hours following reperfusion (Originalmagnification: x200). Decreased hepatic necrosis is seen in the IPO+I/R group compared to the nontreated I/R group. Images are representative liver sections from eight mice per group. Black arrow shows the infiltrated neutrophils and black arrow head shows hepatic cellular necrosis in Figure 2B. (D): Histologicalscores for sinusoidalcongestion, cytoplasmic vacuolization, and hepatocyte necrosis were obtained via analysis of hematoxylin-eosin staining. Data are expressed as the mean ± SD of 8 animals per group. * p < 0.05 compared with I/R group.

Figure 3 Effects of IPO on SOD (A) and MDA (B) levels in liver tissues. To assess the effect of IPO on oxidative stress after liver I/R, MDA and activity of SOD were measured. Hepatic 60 minutes ischemia and 2 hours of reperfusion caused substantialincrease in liver MDA levels and marked decrease in liver SOD activity compared with IPO+I/R group. For allgroups, n = 8. *Significant at p < 0.05 when compared with I/R group.

IPO increases NO, NOS in serum and in liver tissues

To determine whether IPO have protective role through NO-mediated production, we detected the contents of nitric oxide (NO) and nitric oxide synthase (NOS). Hepatic 60 min ischemia and 2 hours of reperfusion markedly reduced both the serum levels of NO, total NOS (TNOS), endothelial NOS (eNOS), iNOS, and production of TNOS, eNOS, iNOS in liver tissues. Compared to I/R group, IPO post-treatment markedly induced NO, eNOS in serum (U/ml: 22.21 ± 1.13 vs. 36.33 ± 7.57), and eNOS in tissue (U/mgprot: 0.038 ± 0.004 vs. 0.058 ± 0.006; I/R vs. IPO) (Figure 4), while no significant difference was found in TNOS [serum(U/ml): 38.514 ± 4.074 vs. 46.147 ± 7.045, tissue(U/mgprot): 0.107 ± 0.045 vs. 0.131 ± 0.038; I/R vs. IPO] both in serum and tissues, and iNOS [serum(U/ml): 12.971 ± 3.055 vs. 10.817 ± 2.116, tissue(U/mgprot): 0.069 ± 0.018 vs. 0.073 ± 0.014; I/R vs. IPO] both in serum and tissues between I/R and IPO+I/R group. Although no significant difference was found in TNOS between I/R and IPO+I/R group, some trends of higher TNOS levels could be seen in the IPO+I/R group. In L-NAME+ IPO and L-NAME+ I/R groups, the serum levels of NO, TNOS, eNOS and iNOS, production of TNOS, eNOS, iNOS in liver tissues were all decreased. These findings suggest that IPO have protective role partially through up-regulating NO and iNOS.

IPO induce HIF-1a and p-Akt expression in liver tissues and modulates I/R-induced inflammatory signaling cascades

To further assess whether the NO-mediated production is associated with HIF-1alpha, we measured the protein expressions of HIF-1alpha and p-Akt by western blot analysis. Western blot analysis results showed that the contents of HIF-1a in liver tissues with IPO post-treated

mice were significantly higher than those in the I/R group (Figure 5). Reports have shown that PI3K signaling pathway is involved in HIF-1a up-regulation in the relevant experiments[19,31]. So we also determined whether IPO altered liver I/R-induced PI3K signaling pathway activation. And Figure 5 shows changes in phosphorylation of Akt upon reperfusion. The ratios of p-Akt and Akt in sham, IPO+I/R, IPO+I/R+L, I/R, I/R +L groups were as follows: 0.91 ± 0.31, 14.53 ± 2.88, 0.84 ± 0.15, 0.64 ± 0.15, 0.57 ± 0.12. So IPO post-treatment markedly enhanced Akt phosphorylation at reperfusion compared to other group (Figure 5), corroborating the role of the PI3K/Akt pathway in the action of IPO.

IPO reduces TNF-a and ICAM-1 mRNA in liver tissues

To determine the expressions of proinflammatory mediators and adhesion molecules, mRNA transcripts for TNF-a and ICAM-1 were assessed. Liver I/R remarkably increased mRNA expression of TNF-a and ICAM-1. IPO significantly abrogated liver warm I/R-induced increases in TNF-a and ICAM-1 mRNA expression (Figure 6A). L-NAME treatment did not decrease the up-regulation of TNF-a and ICAM-1 mRNA expression. The comparison of band intensity ratios of ICAM-1 to b-actin demonstrated that IPO treatment effectively suppressed the TNF-a and ICAM-1 mRNA expression induced by I/R injury (Figure 6B).

IPO reduces TNF-a and ICAM-1 protein in liver tissues

To further determine the protein expression changes of TNF-a and ICAM-1 induced by IPO, we detected these protein expressions by immunohistochemical assay. The over-expressions of TNF-a and ICAM-1 on liver tissues after 4 h of reperfusion were detected (Figure 7B, E). In IPO+I/R group, hepatic I/R-induced increases in TNF-a

Figure 4 Effects of IPO on NO in serum (A), eNOS in serum (B) and in liver tissues (C). To determine whether IPO have protective role through NO-mediated production, the contents of NO and NOS were detected. Compared to I/R group, IPO post-treatment markedly induced NO and eNOS production in serum and in liver tissues. For allgroups, n = 8. * p < 0.05 compared with I/R group.

and ICAM-1 expression were dramatically suppressed (Figure 7C, F). While the up-regulation of TNF-a and ICAM-1 protein expressions were not decreased in the L-NAME+ IPO group. These findings suggest that IPO have a role in modulating the inflammatory process.

L-NAME abolishes the hepatic protection by IPO

To further confirm the NO protection against I/R injury, we also applied a non-selective NOS inhibitor, L-NAME, in the experimental groups. And we found the treatment with L-NAME almost completely abolished the liver protective effect of IPO against I/R-induced hepatic dysfunction (Figures 1, 2, 3, 4, 5, 6).

Discussions

We investigated the potential protective mechanism of IPO on hepatic warm I/R injury. It was observed that IPO post-treatment could effectively attenuate liver injury in a model of mice hepatic warm I/R. The protective effect of IPO was associated with an enhanced, sustained NO generation at reperfusion that was abrogated by NOS inhibition. IPO also increased expression of HIF-1a and phosphorylation of the survival kinase Akt following I/R while inhibiting ROS production, suppressing the overexpression of proinflammatory mediators and adhesion molecules. These results suggest that IPO protects liver from I/R injury, at least in part, by increasing HIF-1a and p-Akt, and suppressing ROS production, which lead to the maintenance of an elevated level of NO.

A series of studies have demonstrated that IPO effectively protects against I/R injuries through NO-mediated

production [17,18]. Unfortunately, little is known about the more detailed protective mechanism of IPO on liver I/R injury. So we demonstrated that IPO, 3 cycles of 10 s of reperfusion followed by 10 s ischemia immediately after 60 min ischemia, exhibited significant protection to the mice liver from I/R injury, as assessed by liver function tests and histology. IPO post-treatment significantly reduced serum levels of ALT, and contributed to significantly lower scores of cytoplasmic vacuolization and massive necrosis compared with the I/R group. L-NAME treatment almost completely abolished the liver protective effect of IPO against I/ R injury morphologically and functionally.

It has been demonstrated by several studies that NO could attenuate I/R injury of different organs [15,16]. Nitric oxide can also cross biological membranes and travel significant distances in cells and tissues [32]. Lang et al recently reported that inhaled NO accelerates restoration of liver function in adults following liver transplantation [33]. It has also been reported that IPO could stimulate production of NO [17,18], so we determined if IPO would protect liver against liver I/R injury through NO-mediated production. We observed the changes of NO levels in serum and tissues, as well as NOS. Until now, three different kinds of NOS have been identified. Previous study has demonstrated that nNOS were expressed in liver tissue of mouse, but it has been reported that nNOS is mainly involved in neuronal signaling and it does not participate in the events involved during I/R [34]. So we detected the serum levels of NO, TNOS, eNOS, iNOS and production of TNOS, eNOS, iNOS in liver tissues.

Sham IPO+IR IP0+1 R+L LR IR+L

Figure 5 Expression of HIF-1alpha, p-Akt and Akt by Western blot. The expression of HIF-lalpha, p-Akt and Akt were detected in liver tissues by western blot analysis. The blot shown is representative of three different experiments with similar results (A). Lain 1-5: sham; IPO+I/R; IPO+I/R+L-NAME; I/R; I/R+L-NAME. The expression of the housekeeping gene, glyceraldehydes 3-phosphate dehydrogenase (GAPDH), served as a control. The expression of HIF-lalpha, and p-Akt were significantly higher in the liver tissues with IPO+I/R group than I/R group, and the signals were decreased in liver tissues with L-NAME (16 mg/kg) pre-treatment. HIF-lalpha, p-Akt and Akt proteins were calculated by densitometry relative to GAPDH, and the results were expressed as ratios after normalization at 100% of the control(B). Data are mean ± SD from three separate experiments. * p < 0.05 compared with other groups. t p < 0.05 compared to sham group.

Hepatic I/R significantly reduced both the serum levels of NO, TNOS, eNOS, iNOS and production of TNOS, eNOS, iNOS in liver tissues. Increased NO, eNOS in serum and eNOS in tissue (Figure 4) were found in IPO+I/R group, while no significant differences were found in TNOS and iNOS in serum and tissues between I/R and IPO+I/R group. L-NAME decreased the serum levels of NO, TNOS, eNOS and iNOS, production of TNOS, eNOS, iNOS in liver tissues. eNOS

was reported to play a beneficial role against I/R injury. It was found that eNOS could lead to amelioration of I/ R-induced liver injury [35,36] and protect against renal I/R injury [37]. eNOS over-expression also could lead to reduced infarct sizes after cardiac I/R injury [36,37]. NO production by eNOS seems to be of central importance in ischemic injury [38,39]. It has been reported that eNOS-derived NO production constitutes a promising therapeutic approach to prevent myocardial I/R injury

I< R4 L IR IPO.lR+l IPOI/R

Figure 6 RT-PCR product of TNF-a and ICAM-1 using template RNA extracted from 4 h post-ischemic liver tissues (A). IPO significantly abrogated liver warm I/R-induced increases in TNF-a and ICAM-1 mRNA expression. Lain 1-5: sham; I/R+L-NAME; I/R; IPO+I/R+L-NAME; IPO+I/R. Representative experiments of three are shown in each case. The mRNA band intensities of TNF-a and ICAM-1 in sham, I/R+L-NAME, I/R, IPO+I/R +L-NAME, IPO+I/R groups were compared as indicated (B). (n = 8). Data are mean ± SD from three separate experiments. * p < 0.05 compared with other groups.

[40]. Our results showed that increased eNOS levels both in serum and tissue using assay kits. So it increased both locally and systemically, and that might contribute to NO production and liver protection. These findings support our hypothesis that the IPO elevates NO and eNOS levels, which in turn reduces or compensates the I/R-induced hepatic injury.

ROS play a critical role in the I/R injury. After warm ischemia, ROS were produced at the moment of reperfusion and promoted the adhesion of leukocytes to microvascular endothelium [41]. Our study showed that IPO post-treatment reversed the increase of MDA levels

to a considerable extent, thereby confirming its antioxidant role in I/R. Furthermore, we showed that SOD activity significantly increased in IPO+I/R group. Total SOD activity is decreased following I/R injury [42], and the decrease would render the tissue susceptible to oxi-dant injury. Therefore, the elevated SOD activity induced by IPO post-treatment may contribute to reduce superoxide radicals following liver I/R. Our results indicated IPO may reduce the oxidative stress caused by hepatic warm I/R injury and attenuate subsequent organ damages (Figure 3). It has been shown that NO may augment antioxidant protection by forming

- ; \ *.* *m * > * r ; • " ; ■ ■ .. - ■. ^ £ » , * * ■*»«. ' * ' ~ c-.*; .v'.\*y

■ V ; - * v ~ . ♦ ,. » t » » . ' ■ ^ " * . "* * * \"i ■ * * « * * % r 1* 1' Î , \ * / i. . i1 »V » . v■'J ¡. % ,, ' ' ■ • » ■ " " * '* D ' • ■ - ' ■ . . ■ v ' • ■, - " ' * , - - V " » .■ . : ■ : :Mf fSZSy 5 ■ rv. ■ ' ■ E F

Figure 7 Immunohistochemical assay of TNF-a (A, B, C) and ICAM-1(D, E, F) on 4 h post-ischemic liver tissue. In the IPO+I/R group, hepatic I/R-induced increases in TNF-a and ICAM-1 expression were dramatically suppressed. (A, D): sham group, (B, E): I/R group, (C, F): IPO+I/R group. Originalmagnification: x400.

intracellular antioxidants (nitrosothiols and glutathione) [43] and by decreasing ROS release through inhibition of NADPH oxidase activity [44]. ROS was also significantly reduced in mice treated with the eNOS enhancer [40]. In turn, bioavailability of NO can be reduced by oxidative inactivation by excessive production of the superoxide anion. Increased generation of superoxide may inhibit the physiological functions of NO [45]. In contrast, SOD can also rapidly scavenge superoxide (O2-) and prolong the vasorelaxant effects of NO [46]. NO responses can be restored by the addition of superoxide dismutase (SOD). So in our study, elevated NO induced by IPO might contribute to reducing ROS release, and also decreased MDA and increased SOD by IPO could contribute to the beneficial effect of NO.

Several reports have shown that HIF-1 activation might attenuate I/R injury [47-49]. Since HIF-1 can upregulate genes intimately involved in ischemic preconditioning (e.g., VEGF [50], and HO-1[51], it becomes an attractive molecular target to limit ischemic or post-ischemic tissue injury. In our study, we found that IPO post-treatment could up-regulate the expression of HIF-1a. The contents of HIF-1a in liver tissues in IPO+I/R group were significantly higher than those in I/R group. It has been shown that NO could influence the levels of HIF-1a in complex ways. NO concentration has a strong influence on whether HIF-1a is stabilized under aerobic conditions [52]. PHD is active under normal oxygen supply and can hydroxylate HIF-1a [53]. Under normoxia, NO can block PHD activity by interacting with enzyme bound Fe2+, directly attenuate hydroxyla-tion of HIF-1a [54] and accumulate HIF-1a. Exposure to NO has been shown to nitrosylate thiols in the HIF-1a protein leading to HIF-1a stabilization [55,56]. NO

can also promote binding of HIF-1a to hypoxia response elements (HREs) in HIF-1a target genes and act as a transcriptional co-activator [57]. NO can act as a diffusible, paracrine messenger to elicit a functional HIF-1 response [58,59]. In turn, unregulated VEGF induced by HIF-1 can activate eNOS in vascular endothelial cells through adenylate cyclase (AC)-protein kinase A (PKA), phosphoinositide 3-kinase (PI3K)-Akt pathways [60], and HIF-1 has been reported to be able to improve the actions of NO [61]. So in our study, elevated NO levels by IPO post-treatment at 2 h after reperfusion contributed to increasing HIF-1a stability, and in turn, up-regulated expression of HIF-1a induced by IPO might also increase the levels of eNOS and NO.

PI3K and its downstream regulated protein Akt as well as eNOS are known to play important roles in survival against ischemia/reperfusion injury. Studies have shown that NO can upregulate the rate of HIF-1a synthesis by activating the PI3K-MAPK (mitogen-acti-vated protein kinase) pathway [19,20]. It was found that the NO donor NOC18 treatment could induce phos-phorylation of Akt, HIF-1a protein expression and HIF-1 transcriptional activation [20]. In our study, western blot analysis results showed that IPO post-treatment could markedly enhance Akt phosphorylation at 2 h after reperfusion compared to control group, and p-Akt was markedly decreased after using L-NAME. So increased NO levels induced by IPO might help in increasing the expression of p-Akt, and then upregulat-ing the rate of HIF-1a synthesis. In turn, Akt has been shown to increase the formation of NO, specifically via the activation of eNOS [62]. Unregulated VEGF induced by HIF-1 can activate eNOS also through PI3K/Akt pathway, and increased the NO production. PI3K is a

redox-sensitive kinase; thus, it may be activated through changes in intracellular ROS levels, leading to eNOS activation and increased NO release [63]. It was reported that ischemic postconditioning's protection involves adenosine receptors and requires PI3-kinase activation [24]. It has been shown that inhibiting PI3K using LY294002 or Wortmannin (Wort) completely abolished IPO-induced protection, so IPO could protect the myocardium by activating the PI3K/Akt pathway [23]. And it was also reported that the PI3K inhibitor LY294002 enlarged infarct in ischemic postconditioned rats, and LY294002 could also abolish the protective effects of IPO on both disease models and healthy hearts, so PI3K/Akt pathway contributes to postcondi-tioning's protection [64,65]. These results also suggested that the PI3K/Akt pathway could play a role in the protective action of liver IPO.

Studies have shown TNF-a could activate neutrophils to release inflammatory mediators and play an important role in I/R injury. TNF-a also caused overexpression of adhesion molecules on both endothelial cells and leukocytes [66], and increased neutrophils aggregation and adhesion to endothelial cells. In this study, the I/R-induced increases in hepatic levels of TNF-a was inhibited in IPO+I/R group (Figure 7) and this effect was confirmed by RT-PCR analysis on TNF-a mRNA in liver tissues (Figure 6). The I/R-induced hepatic accumulation of neutrophils was also decreased following IPO treatment (Figure 2). Thus, inhibition of TNF-a production may prevent the subsequent neutrophils activation. Accumulating evidence indicates that ischemia alone may induce TNF-a mRNA and protein via the generation of ROS [67]. Activation of oxidant-sensitive enzymes involved in TNF-a production represents an additional mechanism by which oxidant stress induces cellular damage. ICAM-1 is also important in the pathogenesis of I/R injury. Hydrogen peroxide can also induce endothelial ICAM-1 through activation of transcriptional factors, such as nuclear transcription factor kB (NF-kB) [68]. Our results showed that increased expression of ICAM-1 was observed 4 h post-reperfusion in untreated mice and IPO effectively suppressed the overexpression of ICAM-1 on liver tissue and abrogated hepatic I/R-induced increase in ICAM-1 mRNA expression (Figure 6). Therefore, the inhibition of I/R-induced increases of ROS following IPO treatment may help in reducing the overexpression of TNF-a and ICAM-1.

Nitric oxide (NO) has been reported to decrease endothelial ICAM-1 mRNA and surface expression, which results in reduction in PMNs adhesion to endothelium stimulated by TNF-a [69]. One mechanism by which NO may modulate the inflammatory process is via its interaction with the Rel/NF-kB family of transcription factors. In the current study, we found that IPO posttreatment

significantly reduced hepatic ICAM-1 mRNA levels during early reperfusion periods, and suppressed neutrophil accumulation in liver. These findings are consistent with previous reports that inhibition of NO synthesis increased ICAM-1 expression and enhanced neutrophil-dependent reperfusion injury in hepatic warm I/R injury [70] and that NO enhancement attenuated neutrophil infiltration and hepatic warm I/R injury [71]. Therefore, up-regulated NO by IPO post-treatment might also have a role in modulate the infammatory process by decreasing the expression of TNF-a and ICAM-1.

Conclusions

In conclusion, our investigations demonstrated that IPO, 3 cycles of 10 s of reperfusion followed by 10 s ischemia, resulted in protection in liver warm I/R injury which was associated with increases in NO, eNOS, SOD, p-Akt and HIF-1a, and decrease in ROS, TNF-a and ICAM-1. IPO induced protection was abrogated in the presence of the NO inhibitor L-NAME. The increased NO concentration produced a cytoprotective environment, resulting in reduced cell death and restoration of hepatic function following reperfusion. Thus, the protection conferred by IPO appears to be mediated by increased NO and HIF-1a productions during reperfusion via the activation of Akt and inhibition of ROS. These findings suggested IPO might have the therapeutic potential through Akt-eNOS-NO-HIF pathway for the better management of liver warm I/R injury.

Acknowledgements

This work is supported by

NationalBasic Research Program of China No. 2009CB522401 NaturalScience Fundation of China (NSFC) No. 30872386

Author details

1Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P. R. China. 2Transplantation Institute, Department of urology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P. R. China.

Authors' contributions

YG, TY and YZ conceived the study, established the design and carried out the experimentalwork. FL, DL and QL performed the animalmodeland relevant experiments. YL participated in the data analysis and provided criticalcomments on the study design and manuscript. LF contributed to the design and coordination of the study, and helped to draft the final version of this manuscript. Allauthors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 13 April 2011 Accepted: 28 October 2011 Published: 28 October 2011

References

1. Carini R, Albano E: Recent insights on the mechanisms of liver preconditioning. Gastroenterology 2003, 125:1480-1491.

2. Oshima Y, Fujio Y, Nakanishi T, Itoh N, Yamamoto Y, Negoro S, Tanaka K, Kishimoto T, Kawase I, Azuma J: STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 2005, 65:428-435.

3. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003, 285:579-588.

4. Cai M, Li Y, Xu Y, Swartz HM, Chen CL, Chen YR, He G: Endothelial NOS activity and myocardial oxygen metabolism define the salvageable ischemic time window for ischemic postconditioning. Am J Physiol Heart Circ Physio 2011, 300:H1069-1077.

5. L0nborg J, Kelbaek H, Vejlstrup N, J0rgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Treiman M, Jensen JS, Engstr0m T: Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010, 3:34-41.

6. Penna C, Tullio F, Moro F, Folino A, Merlino A, Pagliaro P: Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res Cardiol 2010, 105:181-192.

7. Rehni AK, Singh N: Role of phosphoinositide 3-kinase in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked behavioral deficits in mice. Pharmacol Rep 2007, 59:192-198.

8. Liu X, Chen H, Zhan B, Xing B, Zhou J, Zhu H, Chen Z: Attenuation of reperfusion injury by renal ischemic postconditioning: the role of NO. Biochem Biophys Res Commun 2007, 359:628-634.

9. Chen H, Xing B, Liu X, Zhan B, Zhou J, Zhu H, Chen Z: Ischemic postconditioning inhibits apoptosis after renal ischemia/reperfusion injury in rat. Transpl Int 2008, 21364-371.

10. Huang H, Zhang L, Wang Y, Yao J, Weng H, Wu H, Chen Z, Liu J: Effect of ischemic post-conditioning on spinal cord ischemic-reperfusion injury in rabbits. Can J Anaesth 2007, 54:42-48.

11. Santos CHM, Gomes OM, Pontes JCDV, Miiji LNO, Bispo MA: The ischemic preconditioning and postconditioning effect on the intestinal mucosa of rats undergoing mesenteric ischemia/reperfusion process. Acta Cir Bras

2008, 23:22-28.

12. Santos CH, Pontes JC, Miiji LN, Nakamura DI, Galhardo CA, Aguena SM: Postconditioning effect in the hepatic ischemia and reperfusion in rats. Acta Cir Bra 2010,, 25: 163-168.

13. Zhang WX, Yin W, Zhang L, Wang LH, Bao L, Tuo HF, Zhou LF, Wang CC: Preconditioning and postconditioning reduce hepatic ischemia-reperfusion injury in rats. Hepatobiliary Pancreat Dis Int 2009, 8:586-590.

14. Teixeira AR, Molan NT, Kubrusly MS, Bellodi-Privato M, Coelho AM, Leite KR, Machado MA, Bacchella T, Machado MC: Postconditioning ameliorates lipid peroxidation in liver ischemia-reperfusion injury in rats. Acta Cir Bras

2009, 24:52-56.

15. Jalowy A, Schulz R, Heusch G: ATI receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 1999, 10:S129-136.

16. Kubota I, Han X, Opel DJ, Zhao YY, Baliga R, Huang P, Fishman MC, Shannon RP, Michel T, Kelly RA: Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol 2000, 32:1239-1248.

17. Yang XM, Proctor JB, Cui L: Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004, 44:1103-1110.

18. Liu X, Chen H, Zhan B, Xing B, Zhou J, Zhu H, Chen Z: Attenuation of reperfusion injury by renal ischemic postconditioning: the role of NO. Biochem Biophys Res Commun 2007, 359:628-634.

19. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K: Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 2004, 279:2550-2558.

20. Sandau KB, Faus HG, Brune B: Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000, 278:263-267.

21. Zhong Z, Ramshesh VK, Rehman H, Currin RT, Sridharan V, Theruvath TP, Kim I, Wright GL, Lemasters JJ: Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2008, 295:G823-832.

22. Alchera E, Tacchini L, Imarisio C, Dal Ponte C, De Ponti C, Gammella E, Cairo G, Albano E, Carini R: Adenosine-dependent activation of hypoxia-

inducible factor-1 induces late preconditioning in liver cells. Hepatology 2008, 48:230-239.

23. Tsang A, Hausenloy DJ, Mocanu MM: Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-akt pathway. Circ Res 2004, 95:230-232.

24. Yang XM, Philipp S, Downey JM: Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Bas Res Cardiol 2005, 100:57-63.

25. Shao ZH, Wojcik KR, Dossumbekova A, Hsu C, Mehendale SR, Li CQ, Qin Y, Sharp WW, Chang WT, Hamann KJ, Yuan CS, Hoek TL: Grape seed proanthocyanidins protect cardiomyocytes from ischemia and reperfusion injury via Akt-NOS signaling. J Cell Biochem 2009, 107:697-705.

26. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL: Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002, 105:1497-1502.

27. Li J, Zhang H, Wu F, Nan Y, Ma H, Guo W, Wang H, Ren J, Das UN, Gao F: Insulin inhibits tumor necrosis factor-alpha induction in myocardial ischemia/reperfusion: Role of Akt and endothelial nitric oxide synthase phosphorylation. Crit Care Med 2008, 36:1551-1558.

28. Takeda K, Jin MB, Fujita M, Fukai M, Sakurai T, Nakayama M, Taniguchi M, Suzuki T, Shimamura T, Furukawa H, Todo S: A novel inhibitor of Rho-associated protein kinase, Y-27632, ameliorates hepatic ischemia and reperfusion injury in rats. Surgery 2003, 133:197-206.

29. Peralta C, Perales JC, Bartrons R, Mitchell C, Gilgenkrantz H, Xaus C: The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion. Am J Pathol 2002, 160:2111-2122.

30. Sun Y, Oberley LW, Li Y: A simple method for clinical assay of superoxide dismutase. Clin Chem 1988, 34:497-500.

31. Lu DY, Liou HC, Tang CH, Fu WM: Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1alpha. Biochem Pharmacol 2006, 72:992-1000.

32. Wood J, Garthwaite J: Models of the diffusional spread of nitric oxide: implications for neural nitric oxide signalling and its pharmacological properties. Neuropharmacology 1994, 33:1235-1244.

33. Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon JS, Eckhoff DE, Patel RP: Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007, 117:2583-2591.

34. Mathie RT: The hepatic haemodynamic effects of nitric oxide. In In the haemodynamic effects of nitric oxide.. 1 edition. Edited by: Mathie RT, Griffith TM. London: Imperial College Press; 1999:22-51.

35. Harada H, Pavlick KP, Hines IN, Lefer DJ, Hoffman JM, Bharwani S, Wolf RE, Grisham MB: Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: Role of endothelial cell nitric oxide synthase. Proc Natl Acad Sci USA 2003, 100:739-744.

36. Hines IN, Harada H, Bharwani S, Pavlick KP, Hoffman JM, Grisham MB: Enhanced post-ischemic liver injury in iNOS-deficient mice: a cautionary note. Biochem Biophys Res Commun 2001, 284:972-976.

37. Milsom AB, Patel NS, Mazzon E, Tripatara P, Storey A, Mota-Filipe H, Sepodes B, Webb AJ, Cuzzocrea S, Hobbs AJ, Thiemermann C: Ahluwalia A Role for endothelial nitric oxide synthase in nitrite-induced protection against renal ischemia-reperfusion injury in mice. Nitric Oxide 2010, 22:141-148.

38. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M, van Haperen R, de Crom R, Kawashima S, Yokoyama M, Lefer DJ: Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004, 286:H276-H282.

39. Sharp BR, Jones SP, Rimmer DM, Lefer DJ: Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol 2002, 282:H2422-H2426.

40. Frantz S, Adamek A, Fraccarollo D, Tillmanns J, Widder JD, Dienesch C, Schäfer A, Podolskaya A, Held M, Ruetten H, Ertl G, Bauersachs J: The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol 2009, 104:773-779.

41. Granger DN, Benoit JN, Suzuki M, Grisham MB: Leucocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol 1989, 257: G683-688.

Singh I, Gulati S, Orak JK, Singh AK: Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Mol Cell Biochem 1993, 125:97-104.

Ronson RS, Nakamura M, Vinten-Johansen J: The cardiovascular effects and implications of peroxynitrite. Cardiovasc Res 1999, 44:47-59. Fujii H, Ichimori K, Hoshiai K, Nakazawa H: Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process. J Biol Chem 1997, 272:32773-32778.

Kojda G, Harrison D: Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovascular Research 1999, 43:562-571. Murphy ME, Sies H: Reversible conversion of nitroxyl anion to nitric oxide by superoxide dismutase. Proc Natl Acad Sci USA 1991, 88:10860-10864. Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA, Kukreja RC: HIF-1 activation attenuates post-ischemic myocardial injury: a role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 2005, 289:H542-548. Xi L, Taher M, Yin C, Salloum F, Kukreja RC: Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol 2004, 287:H2369-2375.

Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL: Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury.

Circulation 2003, 108:79-85.

Addya S, Shiroto K, Turoczi T, Zhan L, Kaga S, Fukuda S, Surrey S, Duan LJ, Fong GH, Yamamoto F, Maulik N: Ischemic preconditioning mediated cardioprotection is disrupted in heterozygous Flt-1 (VEGFR-1) knockout mice. J Mol Cell Cardiol 2005, 38:345-351.

Patel A, van de Poll MC, Greve JW, Buurman WA, Fearon KC, McNally SJ, Harrison EM, Ross JA, Garden OJ, Dejong CH, Wigmore SJ: Early stress protein gene expression in a human model of ischemic preconditioning.

Transplantation 2004, 78:1479-1487.

Mateo J, Garcia-Lecea M, Cadenas S, Hernandez C, Moncada S: Regulation of hypoxia-inducible factor-1 by nitric oxide through mitochondriadependent and -independent pathways. Biochem J 2003, 376:537-544.

Brune B, Zhou J: Nitric oxide and superoxide: Interference with hypoxic signaling. Cardiovasc Res 2007, 75:275-282. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, Li CY: Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 2007, 26:63-74.

Sumbayev VV, Budde A, Zhou J, Brune B: HIF-1 alpha protein as a target for S-nitrosation. FEBS Lett 2003, 535:106-112.

Brune B, Zhou J: The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Curr Med Chem 2003, 10:845-855.

Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Acquisto F, Makuuchi M, Esumi H: Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001, 276:2292-2298.

Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA: Hypoxic inducible factor 1alpha, extracellular signalregulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004, 101:8894-8899. Zhou J, Fandrey J, Schumann J, Tiegs G, Brune B: NO and TNF-alpha released from activated macrophages stabilize HIF-1alpha in resting tubular LLC-PK1 cells. Am J Physiol Cell Physiol 2003, 284:C439-446. Fukumura D, Kashiwagi S, Jain RK: The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534. Luciano JA, Tan T, Zhang Q, Huang E, Scholz P, Weiss HR: Hypoxia inducible factor-1 improves the actions of nitric oxide and natriuretic peptides after simulated ischemia-reperfusion. Cell Physiol Biochem 2008, 21:421-428.

Hausenloy DJ, Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004, 61:448-460. Ndiaye M, Chataigneau M, Lobysheva I, Chataigneau T, Schini-Kerth VB: Red wine polyphenol-induced, endothelium-dependent NO-mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent

phosphorylation of endothelial NO-synthase in the isolated porcine coronary artery. FASEB J 2005, 19:455-457.

Gao X, Zhang H, Takahashi T, Hsieh J, Liao J, Steinberg GK, Zhao H: The Akt signaling pathway contributes to postconditioning's protection against stroke; the protection is associated with the MAPK and PKC pathways. J

Neurochem 2008, 105:943-55.

Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T, Schaub MC, Zaugg M: Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway.

Cardiovasc Res 2006,, 72: 152-162.

Issekutz TB: Effects of six different cytokines on lymphocyte adherence to microvascular endothelium and in-vivo lymphocyte migration in the rat. J Immunol 1990, 144:2140-2146.

Meldrum DR, Shenkar R, Sheridan BC, Cain BS, Abraham E, Harken AH: Hemorrhage activates myocardial NFkB and increases tumor necrosis factor in the heart. J Mol Cell Cardiol 1997, 29:2849-2854. Yabe Y, Kobayashi N, Nishihashi T, Takahashi R, Nishikawa M, Takakura Y, Hashida M: Prevention of neutrophil-mediated hepatic ischemia/ reperfusion injury by superoxide dismutase and catalase derivatives. J Pharmacol Exp Ther 2001, 298:894-899.

Lindemann S, Sharafi M, Spiecker M, Buerke M, Fisch A, Grosser T, Gierer C, Ibe W, Meyer J, Darius H: NO reduces PMN adhesion to human vascular endothelial cells due to downregulation of ICAM-1 mRNA and surface expression. Thromb Res 2000, 97:113-123.

Liu P, Xu B, Hock CE, Nagele R, Sun FF, Wong PY: NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Am J Physiol 1998, 275:H2191-198.

Shimamura T, Zhu Y, Zhang S, Jin MB, Ishizaki N, Urakami A, Totsuka E, Kishida A, Lee R, Subbotin V, Furukawa H, Starzl TE, Todo S: Protective role of nitric oxide in ischemia and reperfusion injury of the liver. J Am Coll Surg 1999, 188:43-52.

doi:10.1186/1423-0127-18-79

Cite this article as: Guo et al.: Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway. Journal of Biomedical Science 2011 18:79.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

Central